Bo Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo Cheng has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bijun Li
Department of Urology, the Second Affiliated Hospital of Guangdong Medical College, Zhanjiang, 524003, China
1 shared publication - Guosheng Yang
Department of Urology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
1 shared publication - Huanhui Li
Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou, 510317, China
1 shared publication - Jian Bai
Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou, 510317, China
1 shared publication - Kangjian Lin
Department of Urology, Southern Medical University Third Medical College, Guangzhou, 510317, China
1 shared publication - Wei Wang
Department of Urology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.
1 shared publication
Latest Publications
- Open Access
- 8 January 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 27
Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
Docetaxel was used to treat metastatic CRPC patients. However, Doc resistance in prostate cancer (PCa) hinders its clinical application. To understand the underlying mechanisms by which Doc resistance is developed and to find novel therapeutic target to cure Doc resistant PCa has clinical importance. We established Doc resistant cell lines and explored the role of Ezh2 in the development of Doc resistance by overexpressing its cDNA or using its inhibitor. We found that Ezh2 was induced in our established Doc resistant (DocR) cells, which was attributable to the silenced expression of miR-101-3p and miR-138-5p. Blockage of Ezh2 activity by either inhibitor or miRNA mimics could overcome Doc resistance by suppressing Doc-induced cancer stem cells populations. Mechanistically, Ezh2 activity was required for the induced expression of Nanog, Sox2 and CD44 upon Doc treatment. Targeting Ezh2 could overcome Doc resistance.
- 8 January 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 27
Open AccessTargeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
Docetaxel was used to treat metastatic CRPC patients. However, Doc resistance in prostate cancer (PCa) hinders its clinical application. To understand the underlying mechanisms by which Doc resistance is developed and to find novel therapeutic target to cure Doc resistant PCa has clinical importance. We established Doc resistant cell lines and explored the role of Ezh2 in the development of Doc resistance by overexpressing its cDNA or using its inhibitor. We found that Ezh2 was induced in our established Doc resistant (DocR) cells, which was attributable to the silenced expression of miR-101-3p and miR-138-5p. Blockage of Ezh2 activity by either inhibitor or miRNA mimics could overcome Doc resistance by suppressing Doc-induced cancer stem cells populations. Mechanistically, Ezh2 activity was required for the induced expression of Nanog, Sox2 and CD44 upon Doc treatment. Targeting Ezh2 could overcome Doc resistance.